ABSCIENCES (EPA:AB) | Finanzwire

PRESS RELEASE

published on 10/16/2025 at 20:57, 5 months ago

AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB Science provides initial Phase 1 data for combination of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia. Promising results incl. 100% disease control rate and 100% response rate

AB Science AB8939 Phase 1 Data AML Venetoclax
BRIEF

published on 10/14/2025 at 08:41, 5 months 3 days ago

AB Science Reports Promising Initial Data from AML Study

Clinical Trial AML Treatment AB Science AB8939 Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 5 months 3 days ago

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
AB Science releases positive initial data on combination treatment of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia (AML), showing promising results in patients with unfavorable genetic profiles. Virtual conference scheduled with renowned experts in AML

Virtual Conference AB Science AB8939 AML Venetoclax
BRIEF

published on 08/04/2025 at 08:03, 7 months 13 days ago

AB Science Completes EUR 2.55 Million Private Placement

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
PRESS RELEASE

published on 08/04/2025 at 07:58, 7 months 13 days ago

AB Science announces the successful completion of a 2.55 million euros private placement
AB Science successfully completes EUR 2.55 million private placement to fund clinical development. New shares issued with warrants attached

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
BRIEF

published on 07/30/2025 at 07:50, 7 months 18 days ago

AB Science Advances in AML Study With New European Approvals

Regulatory Approval Market Potential AB8939 Venetoclax AML Study
PRESS RELEASE

published on 07/30/2025 at 07:45, 7 months 18 days ago

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining AB8939 with venetoclax for treatment of acute myeloid leukemia

Regulatory Approval AB Science AB8939 Venetoclax Phase I/II Study
BRIEF

published on 07/24/2025 at 08:01, 7 months 24 days ago

AB Science Gains Approval for Phase 3 ALS Masitinib Study Across Europe

Phase 3 Trial ALS AB Science Masitinib European Approval
PRESS RELEASE

published on 07/24/2025 at 07:56, 7 months 24 days ago

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
AB Science receives approval from European countries to initiate Phase 3 study of masitinib in ALS following protocol validation by EMA and FDA

Phase 3 Study ALS AB Science Masitinib EMA
BRIEF

published on 07/08/2025 at 08:06, 8 months 9 days ago

AB Science Completes EUR 1.925 Million Private Placement

Private Placement Share Issuance Biotech Funding AB Science AB8939 Program

Published on 03/17/2026 at 13:30, 5 hours 17 minutes ago

Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 5 hours 17 minutes ago

Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 5 hours 47 minutes ago

Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 13:00, 5 hours 47 minutes ago

High-Resolution Airborne Survey Completed at Music Valley HREE Project
Published on 03/17/2026 at 12:30, 6 hours 17 minutes ago

Revival Gold Targets Underground Resource Growth With Drilling at Beartrack-Arnett Gold Project in Idaho

View all ACCESSWIRE

Published on 03/17/2026 at 18:07, 40 minutes ago

POS-Transaction in Own Shares
Published on 03/17/2026 at 17:58, 49 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 17:45, 1 hour 2 minutes ago

FIGEAC AÉRO: THREE NEW WINS IN MEXICO
Published on 03/17/2026 at 15:30, 3 hours 17 minutes ago

Original-Research: Desert Gold Ventures Inc. (von GBC AG): Buy
Published on 03/17/2026 at 15:19, 3 hours 28 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC

View all EQS

Published on 03/17/2026 at 07:00, 11 hours 47 minutes ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 1 day 1 hour ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News